Dasatinib in the Initial Management of Chronic-Phase Chronic Myeloid Leukemia (CML-CP)


Dasatinib in the Initial Management of Chronic-Phase Chronic Myeloid Leukemia (CML-CP)
Slides from presentations at ASH 2010 and transcribed comments from a recent interview with Susan M O’Brien, MD (1/4/11)

Shah N et al. Dasatinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) in the DASISION trial: 18-month follow-up. Proc ASH 2010;Abstract 206.

Radich JP et al. A randomized Phase II trial of dasatinib 100 mg vs imatinib 400 mg in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): The S0325 Intergroup trial. Proc ASH 2010;Abstract LBA-6.

Dr O'Brien is Professor of Medicine in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas.